Prevalence and Risk Factors of Cervical Squamous Intraepithelial Lesions Among HIV-infected Women in Dar Es Salaam, Tanzania
Overview
Authors
Affiliations
To determine the prevalence and predictors of cervical squamous intraepithelial lesions (SIL) among HIV-infected women in Tanzania, a cross-sectional study was conducted among HIV-infected women at HIV care and treatment clinics. A Papanicolaou (Pap) smear was used as a screening tool for detection of cervical SIL. From December 2006 to August 2009, 1365 HIV-infected women received cervical screening. The median age was 35 (interquartile range [IQR]: 30-42) years, and the median CD4 + cell count was 164 (IQR: 80-257) cells/mm(3). The prevalence of cervical SIL was 8.7% (119/1365). In multivariate analysis, older age (≥50 versus 30-<40 years: prevalence ratio [PR], 2.36; 95% confidence interval [CI], 1.45-3.84, p for trend = 0.001), lower CD4 + cell counts (<100 versus ≥200 cells/mm(3): PR, 1.55; 95% CI, 1.01-2.36, p for trend = 0.03) and cervical inflammation (PR, 1.73; 95% CI, 1.16-2.60, p = 0.008) were associated with an increased risk of cervical SIL. Women with advanced WHO HIV disease stage (IV versus I/II: PR, 3.45; 95% CI, 1.35-8.85, p for trend = 0.01) had an increased risk for high-grade SIL. In resource-limited settings where it is not feasible to provide cervical cancer prevention services to all HIV-infected women, greater efforts should focus on scaling-up services among those who are older than 50 years, with lower CD4 cell counts and advanced HIV disease stage.
Ferede Y, Tassew W, Zeleke A BMC Cancer. 2024; 24(1):678.
PMID: 38831404 PMC: 11149367. DOI: 10.1186/s12885-024-12462-9.
Lemma T, Bala E, Ayana Hordofa M, Solbana L Health Sci Rep. 2024; 7(3):e1972.
PMID: 38476585 PMC: 10928928. DOI: 10.1002/hsr2.1972.
Mungo C, Orango O, Ofner S, Musick B, Yiannoutsos C, Cohen C JCO Glob Oncol. 2024; 10:e2300311.
PMID: 38359369 PMC: 10881085. DOI: 10.1200/GO.23.00311.
Okunowo A, Ugwu A, Ajose A, Kuku J, Okunowo B, Ani-Ugwu N Ecancermedicalscience. 2023; 17:1504.
PMID: 37113726 PMC: 10129382. DOI: 10.3332/ecancer.2023.1504.
Okunade K, Badmos K, Soibi-Harry A, Garba S, Ohazurike E, Ozonu O Acta Cytol. 2022; 67(3):248-256.
PMID: 36516788 PMC: 10238562. DOI: 10.1159/000527905.